Signalling pathways involved in hypoxia-induced renal fibrosis

Minna Liu a, b, #, Xiaoxuan Ning c, #, Rong Li a, #, Zhen Yang a, b, Xiaoxia Yang a, b, Shiren Sun a, *, Qi Qian d, *

a Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China
b State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an, Shaanxi, China
c Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China
d Department of Medicine, Division of Nephrology and hypertension, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN, USA

Received: August 28, 2016; Accepted: November 18, 2016

Abstract

Renal fibrosis is the common pathological hallmark of progressive chronic kidney disease (CKD) with diverse aetiologies. Recent researches have highlighted the critical role of hypoxia during the development of renal fibrosis as a final common pathway in end-stage kidney disease (ESKD), which joints the scientist’s attention recently to exploit the molecular mechanism underlying hypoxia-induced renal fibrogenesis. The scaring formation is a multilayered cellular response and involves the regulation of multiple hypoxia-inducible signalling pathways and complex interactive networks. Therefore, this review will focus on the signalling pathways involved in hypoxia-induced pathogenesis of interstitial fibrosis, including pathways mediated by HIF, TGF-β, Notch, NF-κB, Ang II/ROS and microRNAs. Roles of molecules such as IL-6, IL-18, KIM-1 and ADO are also reviewed. A comprehensive understanding of the roles that these hypoxia-responsive signalling pathways and molecules play in the context of renal fibrosis will provide a foundation towards revealing the underlying mechanisms of progression of CKD and identifying novel therapeutic targets. In the future, promising new effective therapy against hypoxic effects may be successfully translated into the clinic to alleviate renal fibrosis and inhibit the progression of CKD.

Keywords: Signalling pathways • hypoxia • renal fibrosis

Introduction

Renal fibrosis is the common pathological hallmark of almost all advanced kidney diseases with diverse aetiologies, and it has been shown to be the most reliable predictor of CKD progression to end-stage renal failure (ESRD). The mechanisms of interstitial fibrosis in the progression of CKD were successively supposed to be related to proteinuria, oxygen free radicals, vasoactive substances, tubular hypertrophy, hypermetabolism and endothelial dysfunction. However, current knowledge indicates that these putative causes could not account for all aspects of progressive renal diseases completely. In 2000, Fine et al.[1] proposed the chronic hypoxia hypothesis, which

*These authors contributed equally to this work.
*Correspondence to: Shiren SUN
E-mail: sunshiren@medmail.com.cn

E-mail: qian.qi@mayo.edu
doi: 10.1111/jcmm.13060

© 2017 The Authors.
suggested chronic oxygen deprivation, might explain the scar formation in the tubulointerstitial compartment. During the past few decades, this fascinating hypothesis has been vigorously validated both in experimental animals and in humans, and a substantial body of evidence supports the notion of chronic tubulointerstitial hypoxia as a final common pathway leading to ESRD in various pathological conditions [2–5]. And yet, the molecular mechanisms underlying hypoxia driving renal fibrogenesis are not well-elucidated and numerous regulators have been supposed to be implicated in the process directly and indirectly. A comprehensive understanding of hypoxia-regulated signalling pathways involved in the development of chronic kidney injury will undoubtedly promote the identification of novel targets against this final common pathway.

This review will focus on the pathological roles of chronic hypoxia in fibrosis progression of the kidney, and specifically explore how hypoxia promotes the fibrotic response in the interstitial compartment. We review the multiple signalling pathways and molecules involved in hypoxia-induced pathogenesis of interstitial fibrosis, and describe predominant roles of these intracellular cascades and their interactions, in an attempt to unveil the underlying mechanisms of hypoxia-driven renal fibrosis and provide a new insight into anti-fibrotic strategies to alleviate renal fibrosis to halt or retard the CKD progression.

Hypoxia promotes tubulointerstitial fibrosis

Oxygen tension is maintained by the balance between oxygen supply and oxygen consumption. Chronic oxygen deprivation in CKD actually takes place via multiple mechanisms when the balance is broken, ranging from decreases in oxygen supply due to glomerular damage, imbalance of vasoactive substances, peritubular capillaries rarefaction, to increases in oxygen consumption. Together, these mechanisms act at various points in concert to result in chronic hypoxia of the kidney [2, 6–9]. Tubular epithelial cells (TECs) are rendered particularly prone to hypoxic injury due to its high metabolic activity and large oxygen demand [10–12]. Following persistent injury, the epithelial cells initiate inflammatory response by recruiting inflammatory cells to the injured interstitium and secreting a variety of fibrogenic cytokines and inflammatory factors, such as platelet-derived growth factor (PDGF), fibroblast growth factor-2, tumour necrosis factor-α (TNF-1α) and interleukin-6 (IL-6), which subsequently activate fibroblasts and TECs. Activated fibroblasts are described as myofibroblasts which are principally responsible for production of extracellular matrix proteins (ECM) by regulating expression of ECM modifying factors. Furthermore, the epithelial cells are stimulated to undergo apoptosis, cell cycle arrest, and phenotypic transition as epithelial-to-mesenchymal transition (EMT) via loss of their epithelial feature and acquisition of mesenchymal phenotype, contributing to tubular atrophy and ECM accumulation. Eventually, the excess deposition of ECM in interstitium extends distance between the capillaries and nearby nephrons, and then leads to endothelial dysfunction and peritubular microvascular rarefaction, this, in turn, aggravating hypoxia and forming a vicious circle. Together, these fibrogenic events conjunctly result in tissue destruction [13–22]. Renal fibrogenesis is a complex and dynamic process involved in almost all types of renal cells, during which myofibroblasts are considered as the determining cells. The cellular origin of interstitial myofibroblasts has been in dispute, with manifold contributors proposed, such as resident fibroblasts, bone marrow-derived fibrocytes, macrophage (MMT), pericyte and endothelial cells (EndoMT), as well as epithelial cells (EMT) [23–29]. Although lineage tracing studies have doubt the existence of EMT and its contribution to the myofibroblasts pool, developing evidence suggests that EMT programme seems to undergo an incomplete process, and such a partial EMT can arrest cell cycle and thereafter halt renal repair, which leads to tissue dysfunction. In line with this notion, inhibition of EMT has been shown to reverse renal inflammation and fibrosis, indicating the crucial role of EMT in the development of renal fibrosis [30–34].

Signalling pathways involved in hypoxia-induced renal fibrosis

Renal fibrosis is a multifaceted, multilayered cellular response, and multiple signalling pathways can be activated in the hypoxic and fibrotic microenvironment. Based on recent literatures, the most important signal molecules are HIF, TGF-β, Notch, PKC/ERK, PI3K/Akt, NF-κb, Ang II/ROS, microRNAs, ADO, IL-6, IL-18 and KIM-1. Additionally, it is apparent that these signalling pathways cooperate in the execution of scar formation, through enhancing fibroblast proliferation, activation and matrix accumulation (Tables 1 and 2). A comprehensive understanding of these cellular signalling pathways and crosstalks among them in regulating hypoxia-induced tubulointerstitial fibrosis and kidney dysfunction is indispensable and pivotal.

HIF pathway

Hypoxia-inducible factor (HIF) is a well-known master mediator of hypoxia-adaptive responses in a variety of pathophysiological processes in the kidney diseases [35, 36]. Structurally, HIF belongs to basic helix-loop-helix transcription factors and consists of a hypoxically inducible α-subunit and a constitutively expressed nuclear β-subunit, and mammalian genomes contain three genes subtypes of HIF (HIF1-3). Under normoxia, the conserved proline residues of HIF-α subunits are hydroxylated by HIF-prolyl hydroxylase domain containing proteins (PHDs). Then, hydroxylated HIF-α can be recognized by von Hippel–Lindau protein (pVHL) which serves as the substrate recognition component of the ubiquitin ligase complex, and ultimately degraded rapidly by inducing the α-subunit to undergo E3 ubiquitination. In hypoxic condition, the enzymatic activities of PHDs are inhibited, thereby the unmodified HIF-α escapes from entering the destructive process but rather forms a functional complex with HIF-β and its transcriptional co-activators such as CBP/p300. The complex binds to hypoxia-responsive elements (HRE) and transcriptionally regulates numerous HIF-regulated genes, which gives rise to a number of compensatory responses against hypoxia at both cellular and physiological levels in a co-ordinated manner [36, 37].

© 2017 The Authors.
There is controversy regarding the effect of HIF on CKD pathophysiology, which seems to depend on the pathological context. On the one hand, stimulation of HIF and HIF-regulated genes by CoCl2 has been shown to exert renoprotective role in the hypoxic tubulointerstitium in rats with nephritis [38] and hypertensive type 2 diabetes [39]. A similar effect of HIF has been previously reported in cisplatin nephrotoxicity [40]. Besides, there have been studies demonstrated that pharmacological activation of HIF could attenuate renal injury using the rat remnant kidney model of CKD [41–43]. On the other hand, an inappropriate and prolonged activation of HIF is well known to play a pivotal role in initiating and promoting renal fibrogenesis via regulation of multiple signalling pathways in CKD [44–46] (Fig. 1). Firstly, HIF activation can stimulate inflammatory cells proliferation and recruitment to the site of injury in experimental models of CKD, which plays a role in setting up the fibrous scar formation. In addition, activated HIF binds to its pro-fibrogenic downstream genes and induces maladaptive expression of matrix modifying factors directly in hypoxic TECs, such as collagen I, plasminogen activator inhibitor 1 (PAI1), endothelin-1 (ET-1), connective tissue growth factor (CTGF), matrix metallopeptidase 2 (MMP-2) and tissue inhibitor of metalloprotease 1 (TIMP1), which lead to increased production of interstitial collagen and decreased degradation of ECM. Thus, accumulating ECM components subsequently replaces the normal nephrons and fibrosis eventually occurs [47–49]. Apart from promoting ECM deposition, HIF signalling is also involved in facilitating tubular EMT through modulating the expression of EMT regulators such as Snail, Slug, Zeb, SIP1, E12, FOX and CTGF, which enable TECs to lose the expression of epithelial signature and acquire mesenchymal signature to produce ECM [50–54]. Among these EMT regulators, Sun et al. demonstrated that Twist expression played a crucial role in hypoxia-regulated EMT.

Table 1 Signalling pathways mediated hypoxia-induced fibrogenic responses in CKD

| Signalling pathways | Related regulators | Fibrogenic effects | Ref(s) |
|---------------------|-------------------|--------------------|--------|
| HIF                 | Twist, Bmi1, LOXs, PAI1, ET-1, TIMP-1, MMP-2, CTGF, VEGF, TGF-β | Fibroblast activation, inflammatory responses, matrix modifying, collagen synthesis, EMT regulation | [33, 34, 42, 46, 47, 56] |
| TGF-β               | Smads, Timps, Mmps, PHD/HIF, mTORC1, mTORC2, AngII, CTGF, ET-1, VEGF, ILK | Fibroblast activation, inflammatory responses, matrix assembly, collagen synthesis, EMT regulation, cellular apoptosis | [49, 51, 52, 55] |
| Notch               | HIF, LOXs, Snail, Hes1 | Collagen synthesis, EMT regulation | [48, 62, 63] |
| NF-κB               | IL-6, IL-8, TNF-α, MIP-1, MCP-1, INOS, Snail, HIF, CEBPD | Inflammatory responses, EMT regulation, oxidative stress | [64–67] |
| PKC/ERK             | Egr-1, Snail, TGF-β, NF-κB | Inflammatory responses, collagen synthesis, EMT regulation, cellular apoptosis | [68, 69] |
| PI3K/Akt            | Bmi1, BVR, GSK-3β, Snail, | Fibroblast activation, collagen synthesis, EMT regulation, | [46, 73] |
| Notch               | TGF, Snail, Twist, Fsp1, PAI-1, MMP-7 | Fibroblast activation, inflammatory responses, matrix assembly, EMT regulation | [80–82] |
| Ang II/ROS          | PHD/HIF, TIMP-1, ASK1, p38/JNK, TGF-β, PDGF-B, PAI-1, NF-κB | Fibroblast activation, inflammatory responses, oxidative stress, collagen synthesis | [61, 86, 87] |

Table 2 Molecules mediated hypoxia-induced fibrogenic responses in CKD

| Molecules           | Related regulators | Fibrogenic effects | Ref(s) |
|---------------------|--------------------|--------------------|--------|
| miR-124, miR-34a, miR-155 | MMP2, Notch, Snail, HIF, TGF-β | Fibroblast activation, inflammatory responses, EMT regulation | [76, 78, 79] |
| IL-18               | AP-1, TLRs, TNF-α, MIP-2, MCP-1STAT3 | Inflammatory responses, EMT regulation, cellular apoptosis | [89, 92] |
| KIM-1               | IL-6, MCP-1        | Inflammatory responses | [93, 95] |
| ADO                 | A2BR, IL-6, PAI-1  | Fibroblast activation, matrix modifying, collagen synthesis | [97–99] |

VEGF: vascular endothelial growth factor; Fsp1: fibroblast-specific protein1; ILK: integrin-linked kinase; iNOS: inducible nitric oxide synthase; ASK1: apoptosis signal-regulating kinase 1; JNK: c-jun N-terminal kinase.
in renal fibrosis through HIF-1α-dependent signalling [55–57]. It has been indicated by chromatin immunoprecipitation assays and electrophoretic mobility shift that HIF-1α can directly bind to Twist proximal HRE at 317–312 bp in TECs and regulate its expression. Under hypoxic condition, HIF-1α induces Twist transcriptional activation and expression, leading to inhibition of TECs differentiation, myofibroblast accumulation and EMT process in TECs, as indicated by reducing the epithelial markers such as ZO-1 and E-cadherin while enhancing the mesenchymal markers like vimentin and α-smooth muscle actin (α-SMA). Thus, HIF-twist signalling exerts a functional role in EMT-induced renal fibrosis under hypoxic condition. Furthermore, it was reported that, Bmi1, another EMT regulator, was also essential to Twist1-induced repression of E-cadherin contributing to cancer metastasis [58]. Our recent study in kidney diseases has demonstrated that
Bmi1 was involved in hypoxia-triggered EMT in TECs and renal fibrosis, and the region of Bmi1 promoter not only contained the potential HIF-1α-binding site but also the Twist-binding site. Thus, HIF-1 and Twist cooperatively promoted Bmi1 transcriptional activation under low oxygen, then increased the expression of Bmi1 and induced the stabilization of its downstream target genes Snail and E-cadherin by modulating PI3K/Akt pathway, which facilitated EMT process and might explain the underlying mechanisms of chronic hypoxia-induced renal injury by enriching the HIF-Twist signalling. Additionally, it is well known that hypoxia can promote migration of tumour cells via HIF-1-dependent induction of its target gene lysyl oxidases (LOXs) to down-regulate E-cadherin expression [60, 61]. Experimental studies in kidney showed that HIF-1 might drive renal fibrosis in part through up-regulation of LOXs expression [62]. The HIF-mediated up-regulation of LOXs induces the expression of ECM modifying factors and enhances tubular EMT in vivo and vitro. Furthermore, genetic HIF-1 ablation can ameliorate tubulointerstitial fibrosis by reducing extracellular matrix deposition and decreasing inflammatory cell infiltration, which is consistent with the effects caused by pharmacological inhibition of LOXs. Besides, recent reports have also indicated that the LOX-like 2 may interact with the transcriptional repressor Snail to facilitate EMT[63]. Thus, it seems that LOXs emerge as the significant mediators in pro-fibrotic HIF signalling pathway in renal epithelial cells, via up-regulating the expression of ECM modifying factors and facilitating Snail1 activation and EMT.

In addition to hypoxic activation, it worth noting that, other factors also induce fibrogenic effects in CKD via oxygen-independent activation of HIF-1 pathway, including, for example, angiotensin II (Ang II), epidermal growth factor, TNF-1α, interleukin-1, nitric oxide and reactive oxygen species (ROS) [64]. Furthermore, aside from its distinct fibrogenic effects, HIF signalling pathway itself might not be sufficient to promote fibrillogenesis without other cues; the crosstalks between HIF signalling pathway and other intracellular signalling pathways involved in the pathogenesis of CKD progression might be necessary to amplify the pathological fibrogenic response (see below, Fig. 2).

**TGF-β pathway**

Transforming growth factor-β (TGF-β) is the most ubiquitous pro-fibrotic cytokine in progressive renal fibrosis, which signals through Smad-dependent and non-Smad pathways and leads to multiple downstream biological effects [65–67]. In kidney fibroblasts, the expression of TGF-β and Smad genes are increased in response to hypoxia, and subsequently activated TGF-β-Smads can directly stimulate myofibroblast to produce ECM proteins by increasing collagen gene expression and TIMPs but inhibiting MMPs. Meanwhile, TGF-β can synergize with HIF to synthesis certain collagens. Some researchers proposed the pro-fibrotic effect of the interaction between HIF and TGF-β1/SMAD2/3 signalling pathway in chronic nephropathy [68]. Falguni Das et al.[69] demonstrated the involvement of mTORC1 in HIF-1 expression for collagen I production in response to TGF-β. They showed that treatment of TGF-β induced increased

![Fig. 2](image-url)
mTORC1 activity in TECs, which enhanced the expression of HIF1 and subsequently increased collagen I gene transcription. Furthermore, both mTORC1 and mTORC2 signalling can mediate TGF-β1-induced interstitial fibrosis directly though the activation of fibroblast [70–72]. Han et al. [73] found that TGF-β1 could decrease the expression of PHD2 via an Smad2/3-dependent mechanism, accordingly leading to HIF-1α stabilization and up-regulation the expression of fibrogenic genes such as collagen I and PAI expression in RECs. However, over-expression of PHD2 transgene decreased HIF-1α expression and inhibited TGF-β1-regulated EMT, indicating the contribution of PHD2/ HIF-1α signalling pathway to the TGF-β1-induced EMT and renal fibrogenesis. Furthermore, hypoxia and TGF-β1 synergistically induce dysregulated expression of vascular endothelial growth factor and endothelin in the injured tubules, resulting in an insufficient angiogenic response and aggravation of tubulointerstitial hypoxia. Similarly, connective tissue growth factor-β (CTGF), a pro-fibrogenic factor commonly induced by TGF-β1, is also up-regulated by hypoxic stimulation in the development of tubulointerstitial fibrosis. HIF can directly target CTGF at the transcriptional level, activated CTGF then induce its downstream signalling pathways to facilitate renal fibrosis and EMT, such as ERK signalling, NF-κB pathway and Wnt signalling [74–76]. However, CTGF is proposed to play a nephroprotective role of transient hypoxia as HIF-1α reduces the CTGF expression in short-term hypoxia of human proximal TECs [77]. Furthermore, TGF-β-mediated induction of CTGF can be inhibited under hypoxic conditions. Additionally, there exist multiple interactions between TGF-β1 and Ang II under hypoxic environment. As a promoter of fibrogenesis, Ang II can increase transcription and synthesis of TGF-β1 directly and indirectly, further contributing to apoptosis and EMT. Many of the fibrogenic effects of Ang II are mainly mediated by the induction of TGF-β1 and its downstream regulators of inflammation, apoptosis, and ECM synthesis, such as CTGF, PAI-1 and ILK, which also can be directly induced by Ang II and mediate EMT and matrix assembly [78–80].

Notch pathway

It is well-established that Notch signalling plays an active role in EMT-induced organ fibrosis and cancer progression under hypoxia [63, 81]. Notch pathway contains four receptors (Notch1-4) and two types of ligands, Jagged and Delta. When cells experience pathophysiological stresses, the extracellular domain of Notch receptor is bound to Notch ligand, which triggers two proteinase complexes to proteolytically cleave the notch intracellular domain (NIC), released NIC translocates into the nucleus and interacts with transcription cofactors [82]. In kidney fibrosis, Notch regulates the hypoxia-induced EMT mainly by two distinct but synergistic mechanisms. First, hypoxia activates epithelial Notch pathway directly by up-regulating the levels of NIC and its ligand expression, which leads to increased expression of fibronectin, collagen and induction in the key EMT regulator Snail followed by reduction in E-cadherin expression. In contrast, the inhibition of Notch activation in TECs can reduce the degree of renal fibrosis. And second, Notch signalling indirectly controls Snail 1 expression by potentiating crosstalk with hypoxia signalling [81]. The role of Lox in HIF signalling was discussed above. It appears that Notch participates in this process as well by potentiating HIF-1 binding to the LOX promoter and elevates the hypoxia-induced up-regulation of LOX, which also activates the expression of Snail 1. Additionally, upon induction of the hypoxic response, cytoplasmic HIF-1α enhances the release of NIC by increasing the activity of the proteinase complex (γ-secretase), and finally induces the activation of the common target gene like Hes1 [83].

NF-κB pathway

Inflammatory response after sustaining hypoxic injury is considered as a driving force in the development of kidney fibrosis as it initiates the fibrogenic stage. Nuclear factor-κB (NF-κB) pathway mediates inflammatory response primarily, is activated in hypoxic epithelia cells and promotes fibrosis in liver, brain and kidney tissues through regulating its target inflammatory cytokines, adhesion molecules and pro-inflammatory enzymes [84, 85]. NF-κB also controls the expression of EMT inducers (Snail1) and enhances EMT of mammary epithelial cells [86]. Under hypoxia, NF-κB emerges as a transcriptional regulator for HIF-1α and leads to its protein accumulation [87]. For example, CCAAT/enhancer-binding protein δ (CEBPD), an inflammatory factor, is enhanced in TECs under both acute and chronic hypoxic conditions through NF-κB-dependent pathways. Yamaguchi and colleagues [88, 89] suggest that NF-κB pathway provides a significant link between hypoxic signalling and inflammation in RECs by reinforcing CEBPD-mediated HIF pathways; that is, hypoxia and/or inflammation lead to increased NF-κB and CEBPD activity, CEBPD then binds to the promoter in HIF-1α and regulates HIF-1α signalling by transcriptionally increasing its expression level, which in turn contributes to inflammatory cell infiltration and inflammatory cytokines production in the tubulointerstitial area. Thus, the NF-κB/CEBPD/HIF-1 pathway plays a novel role in hypoxic renal injury.

PKC/ERK/Egr-1 pathway

Early growth response-1 (Egr-1) is identified as a vital mediator of fibroblast proliferation and inflammation triggered by various irritants. Aberrant Egr-1 expression or function is associated with scarred process in a variety of human diseases, such as pulmonary fibrosis, emphysema and systemic sclerosis [90, 91]. Egr-1 has also been found to be a hypoxia-responsive transcription factor, and its expression was increased in the rat model of kidney fibrosis. Our previous study provided evidence for active Egr-1 signalling in the hypoxia-triggered EMT and fibrosis in human TECs [92]. Egr-1 activity is mainly determined by the regulation of its biosynthesis. Both in vivo and in vitro studies implied that hypoxic conditions induced the biosynthesis of Egr-1 via the PKC/ERK pathway and that Egr-1 further promoted the renal fibrosis partially through the activation of Snail, which regulated EMT programme by repression of E-cadherin, mucin-1, claudins and occludins. While targeting Egr-1 expression or suppression of ERK1/2 activity can reduce cellular apoptosis and interstitial fibrosis in unilateral ureteric obstruction (UUO) rat kidneys.
Furthermore, Egr-1 can directly induce the expression of collagen gene, matrix remodelling factors and fibrogenic cytokines TGF-β and NF-κB, while Egr-1 deficiency alleviates TGF-β- and NF-κB-induced renal fibrosis and inflammation in TECs [93]. Thus, the PKC/ERK/Egr-1 pathway plays a key role in the hypoxia-regulated EMT and ECM. In addition, adrenomedullin, activated in human TECs cultured under hypoxic conditions, was shown to be involved in this signalling mechanism as it might inhibit hypoxia-induced EMT by increasing the expression of E-cadherin and ZO-1 and decreasing α-SMA and vimentin expression resulted from inhibition of the activation of ERK [94].

**PI3K/Akt pathway**

It is well known that EMT in renal TECs and renal fibrosis induced by hypoxia is closely related to the activation of the PI3K/Akt pathway, as inhibition of PI3K activation attenuated ECM accumulation while the inhibition of Akt resulted in decrease of myofibroblast markers in obstructive nephropathy [95, 96]. It is found that some transactivated EMT regulators such as Bmi1 and Biliverdin reductase (BVR) participate in hypoxia-induced tubulointerstitial fibrosis through PI3K/Akt-dependent pathway [59, 97]. BVR has recently been considered as a serine/threonine/tyrosine kinase that might activate phosphatidylinositol 3-kinase (PI3K) and Akt [98]. First, BVR expression is up-regulated in hypoxic renal tubular cells and remnant kidney, which leads to phosphorylation of Akt. The increase level of Akt phosphorylation then induces change in phosphorylation of GSK-3β and up-regulation of Snail, a downstream target protein of Akt, which can induce activation of fibroblast and accumulation of matrix production in the obstructed kidneys. Furthermore, GSK-3β also activates β-catenin signalling and further enhances the expression of several fibrotic genes [99]. In addition, the relationship between Bmi1 and activation of the PI3K/Akt pathway has been studied recently [100]. It is demonstrated that Bmi1 mediates hypoxia-induced EMT in TECs partly via modulation of the PI3K/Akt/GSK-3β pathway and stabilization of Snail.

**URG11–β-catenin pathway**

Up-regulated gene 11 (URG11), a new HBx-up-regulated gene, was initially found to be involved in hepatocellular carcinoma metastasis via regulation the transcription of β-catenin. Our previous work [101, 102] showed that URG11 also participated in the hypoxia-induced EMT and renal fibrosis and its overexpression was correlated with kidney failure prognosis. Chronic hypoxia stimulated URG11 expression in UUO model, which, in turn, suppressed the expression of E-cadherin, then activated β-catenin and enhanced its nuclear accumulation. In nuclear, β-catenin bond to T cell factor (TCF) and stimulated the transcription of fibrosis-related genes, such as Snail, Twist, Fsp1, PAI-1, MMP-7 and fibronectin, which executed their fibrotic actions by activation of inflammatory cells and myofibroblasts, promoting EMT and ECM assembly [103].

**Ang II/ROS pathway**

Angiotensin II is recognized as one of the factors causing hypoxia in tubulointerstitium via both structural and functional changes of peritubular microvascular system, including decrease in blood flow of peritubular capillaries and inefficient use of oxygen due to oxidative stress [104], which is defined as a dysregulation of antioxidant mechanisms and overproduction of ROS. In turn, chronic renal hypoxia can activate Ang II and induce significant oxidative stress by suppressing the expression of antioxidant such as Cu/Zn-SOD or up-regulating the ROS production such as NAPDH oxidase [105]. Ang II plays a significant role in the pathophysiology of renal inflammation and fibrosis though enhancing tubular apoptosis and EMT [106]. It has also been demonstrated that ROS/PHD/HIF-1 mediates Ang II-induced pro-fibrotic effect in CKD independent of hypoxia [79, 107]. Ang II suppressed HIF-prolyl hydroxylases activities by increasing reactive oxygen species production (H2O2), thereby stimulating HIF-1 accumulation, and consequently inducing TIMP-1 and collagen I/III production in renal cells. HIF-1α may also play a role in AngII-mediated RTEs transdifferentiation. In addition, ANG II and oxidative stress also induce apoptosis signal-regulating kinase 1 (ASK1) in primary tubular cells under hypoxic stress, which then activates p38/JNK signalling and promotes the development of renal inflammation, apoptosis and fibrosis, through up-regulation of collagen I and IV and pro-fibrotic factors such as TGF-β1, PDGF-B and PAI-1 [108]. Both oxidative stress and Ang II can activate NF-κB pathway and subsequently contribute to renal inflammatory injury in UUO [109]. Moreover, prolonged hypoxia and oxidative stress are well known to induce endoplasmic reticulum (ER) stress and activate the unfolded protein response (UPR), thereby leading to cell apoptosis and tubular inflammation [110, 111]. Collectively, the connections among HIF-1, hypoxia, Ang II and ROS highlight the role of metabolic and apoptotic pathways in the progressive chronic renal diseases.

**miRNAs**

It is evident that hypoxia regulates the biogenesis and activity of microRNAs (miRNAs), which are short non-coding RNAs that regulate gene expression through post-transcriptional mechanisms [112]. Numerous researches have demonstrated the vital role of miRNAs in the development of renal fibrosis and EMT. For instance, miR-124, an anti-fibrotic factor, was shown to be associated with hypoxia-dependent MMP2 expression in renal tubular cells. Stephanie Zell et al.[113] showed that hypoxia induced a twofold up-regulation of MMP2 expression and fivefold down-regulation of miR-124 compared to normoxia in TECs. Furthermore, they demonstrated in vitro that overexpression of miR-124 reduces MMP2 protein level, restoring the hypoxia-induced enhanced RPTEC migration. MMP-2 increased migration/proliferation of TECs and enhanced macrophage infiltration by mediating TBM degradation, contributing to the induction of EMT markers and the development of renal fibrosis [114]. Similarly, the regulation of miR-34a expression was involved in hypoxia-induced tubular EMT by targeting Notch signalling [115]. Hypoxia reduced the
miR-34a expression in HK2 cells, which in turn decreased expression of E-cadherin and improved expression of α-SMA and vimentin, thus enhanced EMT process. In contrast, MiR-155 was correlated with hypoxia-associated renal fibrosis as a pro-fibrotic cytokine. Hypoxia induced high expression of miR-155 and promoted fibrosis in proximal tubule cells. Functional experiments further indicated that miR-155 was positively modulated by HIF-1α under hypoxia and the down-regulation of miR-155 was observed in hypoxic renal tubular cells along with HIF-1α knockdown. Up-regulated miR-155 was able to promote the enhancement of α-SMA expression and reduction of E-cadherin expression. What is more, the data also demonstrated that miR-155 is also capable of promoting renal fibrosis by regulating TGF-β1 [116].

Other molecules

Several other molecules have been reported to affect the progression of hypoxia-induced renal fibrosis. Kidney injury molecule-1 (KIM-1), a transmembrane tubular protein initially found in response to acute ischaemic and toxic kidney injury, has been correlated with the pathogenesis of tubulointerstitial inflammation and fibrosis in the chronic injury in CKD. Evidence from both animal models and human diseases showed that sustained hypoxic stimulation could markedly up-regulate the expression of KIM-1 in TECs and sequentially stimulate epithelial cells to secrete cytokines such as IL-6 and monocyte chemotactic protein-1 (MCP-1), which attract inflammatory cells to the tubulointerstitial hypoxic region and enhance inflammatory effects of prolonged hypoxia on tubular cells followed by fibrotic responses [117–119].

IL-18 is an inflammatory cytokine involved in the pathogenesis of renal ischaemia–reperfusion injury and fibrosis [120, 121]. Increasing evidence demonstrates that Toll-like receptors (TLRs) play a role via mediating both pro-inflammatory and pro-fibrotic pathways in IL-18-induced renal fibrosis [122]. In UUO model, the downstream pro-fibrotic effects of IL-18 in TECs are mediated, in part, through alterations in TLR4 expression/signalling. IL-18 up-regulates TLR4 expression via activation of activating protein-1 (AP-1). TLR4 stimulation induces cellular changes consistent with EMT, such as high levels of α-SMA expression and low levels of E-cadherin expression. Furthermore, TLR4 expression is increased in the proximal tubular cells following hypoxia and activates other pro-inflammatory cytokine and chemokine expression (TNF-α, IL-1, IL-6, IL-8, IL-1b, MIP-2 and MCP-1) [123, 124]. In addition, STAT3 has also been demonstrated to mediate IL-18-induced pro-fibrotic response and apoptosis in obstructed kidneys [125].

Adenosine (ADO) is a hypoxia-induced signalling molecule binding to its receptors (ARs) on cell surface. Hypoxic milieu causes extracellular ADO accumulation by repression of the equilibrative nucleoside transporters (ENTs), channels responsible for ADO uptake to be cleared, which can be also regressed by high glucose in the diabetic kidney [126, 127]. In UUO model, prolonged hypoxia occurs and then enhances ADO concentration, leading to activation of the receptor A2BR, which plays a fibrotic role by increased induction of IL-6. IL-6 signalling serves as a pro-fibrotic mediator facilitating collagen production in the ADO-induced renal injury, such as procollagen and PAI-1, resulting in the deposition of ECM components [128, 129]. In line with these observations, increasing ADO level under hypoxia has recently been found to play a role in triggering renal fibroblast activation and proliferation. Thus, ADO signalling contributes to promotion of ECM accumulation and renal interstitial fibrosis [130].

Conclusion and perspective

This article attempts to comprehensively evaluate the available evidence on the role of hypoxia in the renal fibrogenesis with special focus on the functions and crosstalks of the signalling pathways involved in the pathogenesis of hypoxia-induced renal fibrogenesis firstly. It appears that most signalling pathways converge on the EMJ, inflammatory responses and extracellular matrix turnover. As the mechanism underlying scaring process remains vast and more complicated than we are aware of, it is uncertain which one is playing a leading role under chronic hypoxia. However, considering the fact that substantial interactions among two or more signalling pathways synergistically facilitate interstitial fibrosis, it seems that targeting multiple signalling pathways may be a logical strategy to ameliorate interstitial fibrosis. Many anti-fibrotic agents appear to work in animal models, such as prolyl hydroxylase inhibitor, anti-TGF-β antibody, Ang II type-1 receptor inhibitor, aldosterone inhibitor and recombinant human BMP-7 [131]. However, the most difficult challenge ahead is to translate these promising strategies into clinical trials. Hypoxia is likely to be the key pathogenic mechanism in CKD and later ESRD. Targeting hypoxia-mediated processes likely hold promise in devising novel interventional strategies to retard or halt unwanted renal fibrosis and improve clinical outcome in patients with CKD.

Acknowledgements

This work was partially supported by grants from National Nature Science Foundation of China (No. 81670655, No. 81400699, No. 81600520) and Nature Science Foundation of Shaanxi province, China (No. 2014J2007).

Disclosure statement

The authors have no conflict of interest to disclose.

References

1. Fine LG, Bandyopadhyay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia Kidney Int Suppl. 2000;75:S22–6.
2. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17–25.

3. Tanaka T. Expanding roles of the hypoxia-response network in chronic kidney disease. Clin Exp Nephrol. 2016; 20: 835–44.

4. Fu Q, Colgan SP, Shelley CS. Hypoxia: the Force that Drives Chronic Kidney Disease. Clin Med Res. 2016; 14: 15–39.

5. Tanaka T, Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010; 19: 43–50.

6. Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013; 9: 211–22.

7. Heyman SN, Khamaisi M, Rosen S, et al. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol. 2008; 28: 998–1006.

8. Eckardt K, Bernhardt WW, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int. 2005; 68: S46–51.

9. Haase VH. Mechanisms of Hypoxia Responses in Renal Tissue. J Am Soc Nephrol. 2013; 24: 537–41.

10. Louis K, Hertig A. How tubular epithelial cells dictate the rate of renal fibrogenesis? World J Nephrol. 2015; 4: 367–73.

11. Simon N, Hertig A. Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Front Med. 2015; 2: 52.

12. Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol. 2012; 27: 901–9.

13. Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013; 5: 161s–7s.

14. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7: 684–96.

15. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011). 2014; 4: 2–8.

16. Palm F, Nordquist L. Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. Clin Exp Pharmacol Physiol. 2011; 38: 474–80.

17. Manothingam K, Tanaka T, Matsumoto M, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 2004; 65: 871–80.

18. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008; 74: 867–72.

19. Norman JT, Fine LG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol. 2006; 33: 989–96.

20. Mimura I, Nangaku M. The softcaging kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010; 6: 667–78.

21. Zafrai L, Ince C. Microcirculation in acute and chronic kidney diseases. Am J Kidney Dis. 2015; 66: 1083–94.

22. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transpl. 2011; 26: 1132–7.

23. Nikolic-Paterson DJ, Wang S, Lan HY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl (2011). 2014; 4: 34–8.

24. Guerreiro D, Dussaule JC, Kavadas P, et al. Progression of renal fibrosis: the underestimation of endothelial alterations. Fibrogenesis Tissue Repair. 2012; 5: S15.

25. Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008; 19: 2282–7.

26. Leeffler I, Wolf G. Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: fact or Fiction? Cells. 2015; 4: 631–52.

27. Huang S, Susszak K. Epithelial Plasticity versus EMT in Kidney Fibrosis. Trends Mol Med. 2015; 22: 4–6.

28. Kawakami T, Mimura I, Shoji K, et al. Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes. Kidney Int Suppl (2011). 2014; 4: 107–12.

29. Liu Y. New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis. J Am Soc Nephrol. 2010; 21: 212–22.

30. LeBlou VS, Taduri G, O’Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19: 1047–53.

31. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis – evidence for and against. Int J Exp Pathol. 2011; 92: 143–50.

32. Allison SJ. Fibrosis: targeting EMT to reverse renal fibrosis. Nat Rev Nephrol. 2015; 11: 565.

33. Lovisa S, LeBlou VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015; 21: 998–1009.

34. Ovadya Y, Krizhanovsky V. A new Twist in kidney fibrosis. Nat Med. 2015; 21: 975–7.

35. Nangaku M, Inagi R, Miyata T, et al. Hypoxia and Hypoxia-Inducible Factor in Renal Disease. Nephron Exp Nephrol. 2008; 110: e1–7.

36. Nangaku M, Eckardt K. Hypoxia and the HIF system in kidney disease. J Mol Med. 2007; 85: 1325–30.

37. Eckardt K, Bernhardt W, Willam C, et al. Hypoxia-Inducible Transcription Factors and Their Role in Renal Disease. Semin Nephrol. 2007; 27: 363–72.

38. Tanaka T, Matsumoto M, Inagi R, et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 2005; 68: 2714–25.

39. Ohtomo S, Nangaku M, Izuhara Y, et al. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transpl. 2007; 23: 1166–72.

40. Tanaka T. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2005; 289: F1123–33.

41. Deng A, Arndt MAK, Sahriano J, et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. Am J Physiol Renal Physiol. 2010; 299: F1365–73.

42. Song YR, You SJ, Lee YM, et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant. 2009; 25: 77–85.

43. Tanaka T, Kojima I, Ohsu T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest. 2005; 85: 1292–307.

44. Ke Q, Costa M. Hypoxia-Inducible Factor-1 (HIF-1). Mol Pharmacol. 2006; 70: 1469–80.

45. Wang Z, Zhu Q, Li PL, et al. Silencing of hypoxia-inducible factor-1 gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats. Am J Physiol Renal Physiol. 2014; 306:F1236–42.

46. Kimura K, Iwano M, Higgins DF, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol. 2008; 295: F1023–9.

47. Higgins DF, Kimura K, Iwano M, et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle. 2008; 7: 1128–32.

48. Haase VH. Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair. 2012; 5: S16.
Lysyl oxidase isoforms and potential therapeutic opportunities for fibrosis and cancer. *Expert Opin Ther Targets* 2016; 20: 935–45.

62. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J Clin Invest.* 2007; 117: 3810–20.

63. Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. *Proc Natl Acad Sci USA.* 2008; 105: 6392–7.

64. Haase VH. Hypoxia-inducible factors in the kidney. *Am J Physiol Renal Physiol.* 2006; 291: F271–81.

65. Loefler I, Wolf G. Transforming growth factor-β and the progression of renal disease. *Nephrol Dial Transpl.* 2014; 29: i37–45.

66. Meng X, Tang PM, Li J, et al. TGF-β1/Smad signaling in renal fibrosis. *Front Physiol.* 2015; 6: 82.

67. Sutariya B, Jhonsa D, Saraf MN. TGF-β1/beta3 signaling links to progression of renal disease. *Kidney Int Suppl.* 2011; 20: 935–40.

68. Das F, Bera A, Ghosh-Choudhury N, et al. TGF-β1-induced Deptor Suppression Recruits mTORC1 and Not mTORC2 to Enhance Collagen I (α2) Gene Expression. *PLoS One.* 2014; 9: e108608.

69. Jiang L, Xu L, Mao J, et al. Rheed/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. *J Am Soc Nephrol.* 2013; 24: 1114–26.

70. Li J, Ren J, Liu X, et al. Rictor/mTORC2 signaling mediates TGF-β1-induced fibroblast activation and kidney fibrosis. *Kidney Int.* 2015; 119: 1–13.

71. Grahmann F. Halting renal fibrosis: an unexpected role for mTORC2 signaling. *Kidney Int.* 2015; 88: 437–9.

72. Han W, Zhu Q, Hu J, et al. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells. *Biochimica et Biophysica Acta (BBA) - Molecular. Cell Res.* 2013; 1833: 1454–62.

73. Higgins DF, Biju MP, Akai Y, et al. Hypoxic induction of Ctgf is directly mediated by HIF-1. *Am J Physiol Renal Physiol.* 2004; 287: F1223–32.

74. Lee YK, Kim E, Lee JE, et al. Hypoxia Induces Connective Tissue Growth Factor mRNA Expression. *J Korean Med Sci.* 2009; 24: S176.

75. Kok HM, Falke LL, Goldschmeding R, et al. Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. *Nat Rev Nephrol.* 2014; 10: 700–11.

76. Kroening S, Neubauer E, Wessel J, et al. Hypoxia interferes with connective tissue growth factor (CTGF) gene expression in human proximal tubular cell lines. *Nephrol Dial Transpl.* 2009; 24: 3319–25.

77. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. *J Am Soc Nephrol.* 2011; 22: 1189–99.

78. Macconi D, Remuzzi G, Benigni A. Key fibrogenic mediators: old players. *Renin-angiotensin system.* Kidney Int Suppl (2011) 2014; 4: 58–64.

79. Yang F, Chung ACK, Huang XR, et al. Angiotensin II Induces Connective Tissue Growth Factor and Collagen I Expression via Transforming Growth Factor-β-Dependent and -Independent Smad Pathways: the Role of Smad3. *Hypertension.* 2009; 54: 877–84.

80. Bielewicz B, Sirin Y, Si H, et al. Epithelial N otch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. *J Clin Invest.* 2010; 120: 4040–54.

81. Sweetwyne MT, Tao J, Susztak K. Kick it up a notch: notch signaling and kidney fibrosis. *Kidney Int Suppl.* (2011) 2014; 4: 91–6.

82. Borggreve G, Lauth M, Zwijsen A, et al. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. *Biochimica et Biophysica Acta (BBA) - Molecular. Cell Res.* 2016; 1863: 303–13.

83. Grande MT, Perez-Barrionanal F, Lopez-Novoa JM. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. *J Inflamm (Lond).* 2010; 7: 19.

84. Marko L, Vigolo E, Hinze C, et al. Tubular Epithelial NF-kappaB Activity Regulates Ischemic AKI. *J Am Soc Nephrol.* 2016; 27: 2656–69.

85. Julien S, Puig I, Caretti E, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelial mesenchyme transition. *Oncogene.* 2007; 26: 7445–56.

86. Rius J, Guma M, Schachtzurg C, et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. *Nature.* 2008; 453: 807–11.

87. Yamaguchi J, Tanaka T, Eto N, et al. Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein delta. *Kidney Int.* 2015; 88: 262–75.

88. Haase VH. Inflammation and hypoxia in the kidney: friends or foes? *Kidney Int.* 2015; 88: 213–5.
90. Bhattacharya S, Wu M, Fang F, et al. Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol. 2011; 30: 235–42.

91. Cheng JC, Chang HM, Leung PC. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene. 2013; 32: 1041–9.

92. Sun S, Ning X, Zhai Y, et al. Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway. Am J Nephrol. 2014; 39: 436–48.

93. Ho L, Sung J, Shen Y, et al. Egr-1 deficiency protects from renal inflammation and fibrosis. J Mol Med. 2016; 94: 933–42.

94. Zhu T, Yang J, Liu X, et al. Hypoxia-inducible adenornedullin ameliorates the epithelial-to-mesenchymal transition in human proximal tubular epithelial cells. Mol Med Rep. 2015; 11: 3760–6.

95. Zhang X, Liang D, Fan J, et al. Zinc attenuates Tubulointerstitial Fibrosis in Diabetic Nephropathy via Inhibition of HIF Through PI-3K Signaling. Biol Trace Elem Res. 2016; 173: 172–83.

96. Rodriguez-Pena AB, Grande MT, Eleo N, et al. Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int. 2008; 73: 196–209.

97. Zeng R, Yao Y, Han M, et al. Bilverden reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J Am Soc Nephrol. 2008; 19: 380–7.

98. Wegiel B, Baty CJ, Gallo D, et al. Cell surface bilverden reductase mediates bilverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem. 2009; 284: 21369–78.

99. Hwang I, Seo E, Ha H. Wnt/b-catenin signaling: a novel target for therapeutic intervention of fibrotic kidney disease. Arch Pharm Res. 2009; 32: 1653–62.

100. Du R, Xia L, Ning X, et al. Hypoxia-induced 8mi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol Biol Cell. 2014; 25: 2650–9.

101. Du R, Huang C, Bi Q, et al. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and b-catenin. Biochem Biophys Res Co. 2010; 391: 135–41.

102. Du R, Zhao L, Xia L, et al. Association of URG11 and Twist with clinical pathological characteristics and prognosis in patients with IgA nephropathy. Nephrol Dial Transpl. 2013; 28: 2268–76.

103. Tan RJ, Zhou D, Zhou L, et al. Wnt/b-catenin signaling and kidney fibrosis. Kidney Int Suppl. 2014; 4: 84–90.

104. Nangaku M, Fujita T. Activation of the Renin-Angiotensin System and Chronic Hypoxia of the Kidney. Hypertens Res. 2008; 31: 175–84.

105. Zepeda AB, Pessoa A, Castillo RL, et al. Cellular and molecular mechanisms in the hypoxic tissue: role of HIF-1 and ROS. Cell Biochem Funct. 2013; 31: 451–9.

106. Burns WC, Thomas MC. Angiotensin II and its role in tubulointerstitial fibrosis associated with chronic kidney disease. Cells Tissues Organs. 2011; 193: 74–84.

107. Wang Z, Tang L, Zhu Q, et al. Hypoxia-inducible factor-1a contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int. 2011; 79: 300–10.

108. Ma FY, Tesch GH, Nikolic-Paterson DJ. ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol. 2014; 307: F1263–73.

109. Ruiz-Ortega M, Ruperez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006; 21: 16–20.

110. Small DM, Coombes JS, Bennett N, et al. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology. 2012; 17: 311–21.

111. Ding W, Cai Y, Wang W, et al. Adiponectin protects the kidney against chronic intermittent hypoxia-induced injury through inhibiting endoplasmic reticulum stress. Sleep Breath. 2016; 20: 1099–74.

112. Nallamshetty S, Chan SY, Loscalzo J. Zinc Atteniomycin inhibits hypoxic tissue: role of HIF-1 and ROS. Kidney Int Suppl (2011) 2016; 7: e30771.

113. Bani-Hani AH, Leslie JA, Asanuma H, et al. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int. 2009; 76: 500–11.

114. Yano T, Nakazaki Y, Kinoshita K, et al. The pathological role of IL-18Ra in renal ischemia/reperfusion injury. Lab Invest. 2015; 95: 78–91.

115. Meldrum KK, Zhang H, Hile KL, et al. Profibrotic Effect of Interleukin-18 in HK-2 Cells Is Dependent on Stimulation of the Toll-like Receptor 4 (TLR4) Promoter and Increased TLR4 Expression. J Biol Chem. 2012; 287: 40391–9.

116. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007; 117: 2847–59.

117. Liu WH, Lin M, Tang SC. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl (2011) 2014; 4: 20–5.

118. Matsu F, Rhee A, Hile KL, et al. IL-18 induces profibrotic renal tubular cell injury via STAT3 activation. Am J Physiol Renal Physiol. 2013; 305: F1014–21.

119. Eltzschig HK, Abdulla P, Hoffman E, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005; 202: 1493–505.

120. Kretschmar C, Oyarzun C, Villablanca C, et al. Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: implication in Diabetic
Nephropathy. *PLoS One*. 2016; 11: e147430.

128. Dai Y, Zhang W, Wen J, *et al.* A2B adenosine receptor-mediated induction of IL-6 promotes CKD. *J Am Soc Nephrol*. 2011; 22: 890–901.

129. Tang J, Jiang X, Zhou Y, *et al.* Increased adenosine levels contribute to ischemic kidney fibrosis in the unilateral ureteral obstruction model. *Exp Ther Med*. 2015; 9: 737–43.

130. Tang J, Jiang X, Zhou Y, *et al.* Effects of A2BR on the biological behavior of mouse renal fibroblasts during hypoxia. *Mol Med Rep*. 2015; 11: 4397–402.

131. Decleves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. *Nat Rev Nephrol*. 2014; 10: 257–67.